Cargando…
Genome-editing technologies for gene correction of hemophilia
Hemophilia is caused by various mutations in blood coagulation factor genes, including factor VIII (FVIII) and factor IX (FIX), that encode key proteins in the blood clotting pathway. Although the addition of therapeutic genes or infusion of clotting factors may be used to remedy hemophilia’s sympto...
Autores principales: | Park, Chul-Yong, Lee, Dongjin R., Sung, Jin Jea, Kim, Dong-Wook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999461/ https://www.ncbi.nlm.nih.gov/pubmed/27357631 http://dx.doi.org/10.1007/s00439-016-1699-x |
Ejemplares similares
-
Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019) -
Nonfactor Therapies for Hemophilia
por: Young, Guy
Publicado: (2023) -
Management of hemophilia in Korea: the past, present, and future
por: Choi, Eun Jin
Publicado: (2014) -
Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia
por: Lee, Jeong Hyeon, et al.
Publicado: (2022) -
The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
por: Wang, Michael, et al.
Publicado: (2022)